Background: Choriocarcinoma most frequently arises in a complete hydatidiform mole. Less common are cases following a normal pregnancy or a nonmolar abortion. Its occurrence after a partial hydatidiform mole is extremely rare.

Case Report: Here we report a choriocarcinoma in situ diagnosed after dilation and curettage for a first tri- mester partial hydatidiform mole. The diagnosis was con- firmed by immunohistochemistry, fluorescent in situ hybridization, and microsatellite instability genotyping of the products of conception and blood of the mother and father. We demonstrated a diandric triploidy. At the time of diagnosis CT scan showed lung metastasis. The pa- tient was classified as high-risk gestational trophoblas- tic neoplasia and treated with high-dose methotrexate- etoposide.

Conclusion: This is the first reported case of a cho- riocarcinoma arising in a first trimester partial mol.

Download full-text PDF

Source

Publication Analysis

Top Keywords

hydatidiform mole
16
partial hydatidiform
12
choriocarcinoma situ
8
partial
4
situ partial
4
hydatidiform
4
mole
4
mole case
4
case report
4
report background
4

Similar Publications

Introduction: Gestational trophoblastic disease (GTD) encompasses a constellation of rare to common gynecologic conditions stemming from aberrant gestations with distinct genetic backgrounds and variable degrees of trophoblast proliferation of either neoplastic or non-neoplastic nature. GTD is categorized into hydatidiform moles and gestational trophoblastic neoplasms, and their clinical outcomes vary widely across different subtypes. Prompt and accurate diagnosis plays a pivotal role in the effective management and prognostication of patients.

View Article and Find Full Text PDF

Objective: To evaluate the efficacy of actinomycin D (ActD) as prophylactic chemotherapy (P-chem) in patients with high-risk complete hydatidiform mole (Hr-CHM) on progression to gestational trophoblastic neoplasia (GTN).

Methods: From 1996 to 2023, 426 Hr-CHMs were selected in a cohort of 1623 patients with gestational trophoblastic disease (GTD). From 1996 to 2023, 290 patients with Hr-CHMs received a single bolus dose of Act-D at the time of uterine evacuation (Hr-CHM P-chem group); 136 with the same risk factors did not receive P-chem (Hr-CHM control group).

View Article and Find Full Text PDF

Aim: While manual vacuum aspiration (MVA) is commonly employed for early first-trimester abortions, its effectiveness in treating hydatidiform mole is still unclear. This study sought to evaluate the efficacy and safety of MVA in comparison to dilation and curettage (D&C) for managing hydatidiform mole.

Methods: We conducted a retrospective review of medical records for 198 patients with hydatidiform mole treated at Nagoya University Hospital between 2004 and 2023.

View Article and Find Full Text PDF

Vascular retained products of conception at cesarean scar mimicking hydatidiform mole.

J Med Ultrason (2001)

January 2025

Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto-City, Kumamoto, 860-8556, Japan.

View Article and Find Full Text PDF

Enhancing Clinical Applications by Evaluation of Sensitivity and Specificity in Whole Exome Sequencing.

Int J Mol Sci

December 2024

Bioinformatics Analysis Team, Research Core Center, Research Institute, National Cancer Center, Goyang 10408, Gyeonggi-do, Republic of Korea.

The cost-effectiveness of whole exome sequencing (WES) remains controversial due to variant call variability, necessitating sensitivity and specificity evaluation. WES was performed by three companies (AA, BB, and CC) using reference standards composed of DNA from hydatidiform mole and individual blood at various ratios. Sensitivity was assessed by the detection rate of null-homozygote (N-H) alleles at expected variant allelic fractions, while false positive (FP) errors were counted for unexpected alleles.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!